Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Advances in Treatment of Pulmonary Embolism
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances in Treatment of Pulmonary Embolism

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".

Deadline for manuscript submissions: closed (20 March 2025) | Viewed by 7293

Special Issue Editors

Dr. Seth I. Sokol

E-Mail Website
Guest Editor
Departments of Medicine, Division of Cardiology, New York City Health + Hospitals/Jacobi Medical Center and the Albert Einstein College of Medicine, Bronx, NY, USA
Interests: pulmonary embolism; interventional cardiology; endovascular interventions; vascular medicine
Dr. Thomas M. Todoran

E-Mail Website
Guest Editor
Divisions of Cardiology and Vascular Surgery, Medical University of South Carolina, Charleston, SC, USA
Interests: peripheral vascular disease; interventional cardiology; endovascular treatment; vascular medicine

Special Issue Information

Dear Colleagues,

Acute pulmonary embolism remains a leading cause of cardiovascular death and morbidity worldwide. Despite the advances in diagnosis and treatment of acute pulmonary embolism that have been made over recent years, many gaps remain in the literature regarding evidence-based approaches to the treatment of pulmonary embolism. As a result, treatment guidelines rely heavily on expert opinion.

This Special Issue on “Advances in Treatment of Pulmonary Embolism” in collaboration with The PERT ConsortiumTM seeks to update the current state of knowledge regarding diagnosis, risk stratification, multidisciplinary approaches utilizing pulmonary embolism response teams (PERT), medical and interventional treatments, and the appropriate follow-up of patients with pulmonary embolism.

We are seeking original research, review articles, and expert opinion pieces for this Special Issue. Suggested topics include: diagnosis of acute pulmonary embolism, imaging in pulmonary embolism, assessing the risk of patients with acute pulmonary embolism, pulmonary embolism response teams (PERT), percutaneous thrombectomy, catheter-directed thrombolysis, surgical thrombectomy, systemic thrombolysis, the role of mechanical circulatory support in the treatment of acute pulmonary embolism, and acute and long term anticoagulation in patients with pulmonary embolism.

Dr. Seth I. Sokol
Dr. Thomas M. Todoran
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute pulmonary embolism
  • diagnosis
  • risk stratification
  • medical treatment
  • anticoagulation
  • interventional treatments
  • advanced therapies
  • PERT

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 544 KiB  
Article
Inflammatory and Metabolic Predictors of Mortality in Pulmonary Thromboembolism: A Focus on the Triglyceride–Glucose Index and Pan-Immune Inflammation Value
by Murat Bilgin, Emre Akkaya and Recep Dokuyucu
J. Clin. Med. 2024, 13(19), 6008; https://doi.org/10.3390/jcm13196008 - 9 Oct 2024
Cited by 5 | Viewed by 1262
Abstract
Objectives: We aimed to evaluate the importance of metabolic and inflammatory markers, specifically the Triglyceride–Glucose Index (TGI) and pan-immune inflammation value (PIV), in predicting mortality among patients diagnosed with pulmonary thromboembolism (PTE). Materials and Methods: A total of 450 patients diagnosed [...] Read more.
Objectives: We aimed to evaluate the importance of metabolic and inflammatory markers, specifically the Triglyceride–Glucose Index (TGI) and pan-immune inflammation value (PIV), in predicting mortality among patients diagnosed with pulmonary thromboembolism (PTE). Materials and Methods: A total of 450 patients diagnosed with PTE between December 2018 and December 2023 were included in his study. The diagnosis of PTE was confirmed by clinical presentation, laboratory tests, and imaging studies such as computed tomography pulmonary angiography (CTPA). Data were obtained from medical records, including demographic information, medical history, laboratory results, and clinical outcomes. Results: In terms of age, non-survivors were older on average (66.1 ± 11.8 years) compared to survivors (58.3 ± 12.4 years) (p = 0.03). In terms of gender, 55% of non-survivors and 45% of survivors were male (p = 0.111). Non-survivors had higher BMIs (28.3 ± 5.1) than survivors (25.7 ± 4.5) (p = 0.04). In terms of hypertension, 40% of non-survivors and 30% of survivors had hypertension (p = 0.041). In terms of diabetes, 35% of those who did not survive and 20% of those who survived had diabetes (p = 0.001). In terms of smoking, 25% of non-survivors and 15% of survivors smoke (p = 0.022). In terms of TGI, non-survivors had higher TGI values (12.1 ± 1.5) than survivors (5.9 ± 1.2) (p < 0.001). In terms of PIV, non-survivors had significantly higher PIV (878.2 ± 85.4) than survivors (254.5 ± 61.1) (p < 0.001). The risk factors found to be significantly associated with differentiation in the multiple logistic regression analysis included age, BMI, TGI, and PIV (p = 0.005, p = 0.002, p = 0.013, and 0.022, respectively). As a result, according to ROC analysis for patients who are non-survivors, age, BMI, TGI, and PIV were significant prognostic factors. The cut-off points for these values were >60, >27, >10, and >500, respectively. Conclusions: the TGI and PIV are strong markers for predicting mortality in PTE patients. The independent predictive value of age and BMI further demonstrates their role in risk stratification. We think that high TGI values and PIVs reflect underlying metabolic and inflammatory disorders that may contribute to worse outcomes in these patients. Full article
(This article belongs to the Special Issue Advances in Treatment of Pulmonary Embolism)
►▼ Show Figures

Figure 1

12 pages, 1085 KiB  
Article
Comparison of In-Hospital Outcomes between Early and Late Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: A Retrospective Observational Study
by Majd Al Deen Alhuarrat, Kirolos Barssoum, Medhat Chowdhury, Sheetal Vasundara Mathai, Miriam Helft, Michael Grushko, Prabhjot Singh, Hani Jneid, Afaq Motiwala, Robert T. Faillace and Seth I. Sokol
J. Clin. Med. 2024, 13(4), 1093; https://doi.org/10.3390/jcm13041093 - 15 Feb 2024
Cited by 1 | Viewed by 1552 | Correction
Abstract
The purpose of this study is to evaluate whether early initiation of catheter-directed thrombolysis (CDT) in patients presenting with acute pulmonary embolism is associated with improved in-hospital outcomes. A retrospective cohort was extracted from the 2016–2019 National Inpatient Sample database, consisting of 21,730 [...] Read more.
The purpose of this study is to evaluate whether early initiation of catheter-directed thrombolysis (CDT) in patients presenting with acute pulmonary embolism is associated with improved in-hospital outcomes. A retrospective cohort was extracted from the 2016–2019 National Inpatient Sample database, consisting of 21,730 weighted admissions undergoing CDT acute PE. From the time of admission, the sample was divided into early (<48 h) and late interventions (>48 h). Outcomes were measured using regression analysis and propensity score matching. No significant differences in mortality, cardiac arrest, cardiogenic shock, or intracranial hemorrhage (p > 0.05) were found between the early and late CDT groups. Late CDT patients had a higher likelihood of receiving systemic thrombolysis (3.21 [2.18–4.74], p < 0.01), blood transfusion (1.84 [1.41–2.40], p < 0.01), intubation (1.33 [1.05–1.70], p = 0.02), discharge disposition to care facilities (1.32 [1.14–1.53], p < 0.01). and having acute kidney injury (1.42 [1.25–1.61], p < 0.01). Predictors of late intervention were female sex, nonwhite race, and weekend admission (p < 0.01). This study represents a comprehensive evaluation of outcomes associated with the time interval for initiating CDT, revealing reduced morbidity with early intervention. Additionally, it identifies predictors associated with delayed CDT initiation. The broader ramifications of these findings, particularly in relation to hospital resource utilization and health disparities, warrant further exploration. Full article
(This article belongs to the Special Issue Advances in Treatment of Pulmonary Embolism)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 4488 KiB  
Review
Mechanical Support in High-Risk Pulmonary Embolism: Review Article
by Amer N. Kadri, Razan Alrawashdeh, Mohamad K. Soufi, Adam J. Elder, Zachary Elder, Tamam Mohamad, Eric Gnall and Mahir Elder
J. Clin. Med. 2024, 13(9), 2468; https://doi.org/10.3390/jcm13092468 - 24 Apr 2024
Cited by 4 | Viewed by 3739
Abstract
Acute pulmonary embolism (PE) may manifest with mild nonspecific symptoms or progress to a more severe hemodynamic collapse and sudden cardiac arrest. A substantial thrombotic burden can precipitate sudden right ventricular strain and failure. Traditionally, systemic thrombolytics have been employed in such scenarios; [...] Read more.
Acute pulmonary embolism (PE) may manifest with mild nonspecific symptoms or progress to a more severe hemodynamic collapse and sudden cardiac arrest. A substantial thrombotic burden can precipitate sudden right ventricular strain and failure. Traditionally, systemic thrombolytics have been employed in such scenarios; however, patients often present with contraindications, or these interventions may prove ineffective. Outcomes for this medically complex patient population are unfavorable, necessitating a compelling argument for advanced therapeutic modalities or alternative approaches. Moreover, patients frequently experience complications beyond hemodynamic instability, such as profound hypoxia and multiorgan failure, necessitating assertive early interventions to avert catastrophic consequences. The existing data on the utilization of mechanical circulatory support (MCS) devices are not exhaustive. Various options for percutaneous MCS devices exist, each possessing distinct advantages and disadvantages. There is an imminent imperative to develop a tailored approach for this high-risk patient cohort to enhance their overall outcomes. Full article
(This article belongs to the Special Issue Advances in Treatment of Pulmonary Embolism)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop